150.09
price down icon1.35%   -2.055
after-market 시간 외 거래: 150.09
loading
전일 마감가:
$152.15
열려 있는:
$147.56
하루 거래량:
514.47K
Relative Volume:
1.19
시가총액:
$9.02B
수익:
$354.82M
순이익/손실:
$-462.76M
주가수익비율:
-18.52
EPS:
-8.105
순현금흐름:
$-460.07M
1주 성능:
-4.97%
1개월 성능:
-1.21%
6개월 성능:
+6.48%
1년 성능:
+0.39%
1일 변동 폭
Value
$147.56
$155.45
1주일 범위
Value
$143.81
$158.54
52주 변동 폭
Value
$111.09
$169.37

Ascendis Pharma A S Adr Stock (ASND) Company Profile

Name
명칭
Ascendis Pharma A S Adr
Name
전화
-
Name
주소
-
Name
직원
1,017
Name
트위터
Name
다음 수익 날짜
2024-12-13
Name
최신 SEC 제출 서류
Name
ASND's Discussions on Twitter

ASND을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ASND
Ascendis Pharma A S Adr
150.09 9.02B 354.82M -462.76M -460.07M -8.105
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-01-07 개시 UBS Buy
2024-09-05 업그레이드 Oppenheimer Perform → Outperform
2024-06-25 업그레이드 TD Cowen Hold → Buy
2024-05-31 개시 Stifel Buy
2023-12-20 개시 Jefferies Buy
2023-06-14 재개 Credit Suisse Neutral
2023-04-05 다운그레이드 Oppenheimer Outperform → Perform
2023-04-04 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2023-04-03 다운그레이드 Credit Suisse Outperform → Neutral
2022-10-20 개시 Goldman Buy
2022-08-30 재개 Berenberg Buy
2022-03-28 재개 Wedbush Outperform
2022-03-15 업그레이드 BofA Securities Neutral → Buy
2022-03-01 개시 Citigroup Buy
2022-02-14 업그레이드 Oppenheimer Perform → Outperform
2022-01-06 개시 Cowen Market Perform
2021-12-08 개시 Wells Fargo Overweight
2021-10-20 다운그레이드 BofA Securities Buy → Neutral
2021-03-30 다운그레이드 Oppenheimer Outperform → Perform
2021-03-11 재개 Stifel Buy
2020-12-17 개시 Berenberg Buy
2020-09-14 재개 JP Morgan Overweight
2020-03-20 개시 Oppenheimer Outperform
2019-10-11 개시 Morgan Stanley Overweight
2019-03-25 개시 Evercore ISI Outperform
2019-01-24 개시 Cantor Fitzgerald Overweight
2019-01-24 업그레이드 Leerink Partners Mkt Perform → Outperform
2018-06-26 개시 Stifel Buy
2018-04-02 재확인 Leerink Partners Mkt Perform
2017-05-11 개시 JP Morgan Overweight
2017-03-09 다운그레이드 Leerink Partners Outperform → Mkt Perform
2017-02-09 개시 Credit Suisse Outperform
2016-09-26 개시 Wedbush Outperform
모두보기

Ascendis Pharma A S Adr 주식(ASND)의 최신 뉴스

pulisher
Mar 19, 2025

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView

Mar 19, 2025
pulisher
Mar 18, 2025

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Ascendis Pharma ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Investor's Business Daily

Mar 18, 2025
pulisher
Mar 18, 2025

Autohome ADR Joins Elite Club Of Stocks With RS Ratings Over 90 - Inkl

Mar 18, 2025
pulisher
Mar 17, 2025

European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView

Mar 17, 2025
pulisher
Mar 13, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Thursday Trading - TradingView

Mar 13, 2025
pulisher
Mar 12, 2025

European Equities Traded in the US as American Depositary Receipts Lower Wednesday - TradingView

Mar 12, 2025
pulisher
Mar 09, 2025

Ascendis Pharma A/S Sponsored ADR to Host Earnings Call - ACCESS Newswire

Mar 09, 2025
pulisher
Mar 07, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView

Mar 07, 2025
pulisher
Mar 06, 2025

Ascendis Pharma at TD Cowen Conference: Strategic Growth in Rare Diseases - Investing.com

Mar 06, 2025
pulisher
Feb 26, 2025

Ascendis Pharma's SWOT analysis: stock outlook amid Yorvipath success, Skytrofa challenges - Investing.com

Feb 26, 2025
pulisher
Feb 25, 2025

Cantor Fitzgerald lifts Ascendis Pharma target to $200, maintains Overweight - Investing.com

Feb 25, 2025
pulisher
Feb 20, 2025

Why Is BioMarin Stock Trading Higher On Thursday? - Benzinga

Feb 20, 2025
pulisher
Feb 20, 2025

Stocks To Watch: Kontoor Brands Sees RS Rating Rise To 84 - Inkl

Feb 20, 2025
pulisher
Feb 19, 2025

Stocks To Watch: Ascendis Pharma ADR Sees RS Rating Rise To 82 - Investor's Business Daily

Feb 19, 2025
pulisher
Feb 18, 2025

Stocks To Watch: Pony AI ADR Sees RS Rating Jump To 92 - Inkl

Feb 18, 2025
pulisher
Feb 17, 2025

Ascendis Pharma's SWOT analysis: promising pipeline fuels stock potential - Investing.com

Feb 17, 2025
pulisher
Feb 13, 2025

ASND’s price-to-free cash flow ratio: A closer look at its relevance - US Post News

Feb 13, 2025
pulisher
Feb 12, 2025

Earnings call transcript: Ascendis Pharma Q4 2024 sees revenue rise - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

Ascendis Pharma launches $25 million share buyback - Investing.com

Feb 12, 2025
pulisher
Feb 12, 2025

European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView

Feb 12, 2025
pulisher
Feb 11, 2025

Cantor Fitzgerald maintains Ascendis Pharma Overweight rating By Investing.com - Investing.com South Africa

Feb 11, 2025
pulisher
Feb 11, 2025

Cantor Fitzgerald maintains Ascendis Pharma Overweight rating - Investing.com

Feb 11, 2025
pulisher
Feb 03, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading - MSN

Feb 03, 2025
pulisher
Jan 29, 2025

JPMorgan raises Ascendis Pharma target to $167, keeps Overweight - Investing.com

Jan 29, 2025
pulisher
Jan 29, 2025

Ascendis Pharma A/S (ASND) Expected to Announce Earnings on Wednesday - Defense World

Jan 29, 2025
pulisher
Jan 15, 2025

Goldman Sachs retains Buy on Ascendis Pharma shares, cites legal action - Investing.com

Jan 15, 2025
pulisher
Jan 13, 2025

BioMarin sues Ascendis Pharma over patent infringement - Investing.com

Jan 13, 2025
pulisher
Jan 13, 2025

Ascendis Pharma stock falls on missed Skytrofa revenue forecast - Investing.com

Jan 13, 2025
pulisher
Jan 12, 2025

European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading - MSN

Jan 12, 2025
pulisher
Jan 07, 2025

European Equities Traded in US as American Depositary Receipts Surge on Monday - MSN

Jan 07, 2025
pulisher
Jan 07, 2025

UBS starts Ascendis Pharma stock at Buy, optimistic on upcoming launches - Investing.com

Jan 07, 2025
pulisher
Dec 31, 2024

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN

Dec 31, 2024
pulisher
Dec 29, 2024

European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN

Dec 29, 2024
pulisher
Dec 20, 2024

Ascendis Pharma's SWOT analysis: stock poised for growth amid challenges - Investing.com

Dec 20, 2024
pulisher
Dec 18, 2024

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading - MSN

Dec 18, 2024
pulisher
Dec 16, 2024

Ascendis Pharma target raised to $194 on positive trial results - Investing.com

Dec 16, 2024
pulisher
Dec 07, 2024

European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN

Dec 07, 2024
pulisher
Nov 21, 2024

Ascendis Pharma's SWOT analysis: stock faces growth hurdles amid pipeline promise - Investing.com

Nov 21, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

European Equities Traded in the US as American Depositary Move Higher in Monday Trading - MSN

Nov 20, 2024
pulisher
Oct 21, 2024

TD Cowen boosts Ascendis stock target, sees Q3 Skytrofa growth lagging but long-term outlook intact - Investing.com

Oct 21, 2024
pulisher
Oct 14, 2024

Nothing is Better Than Ascendis Pharma A/S ADR (ASND) stock at the moment - SETE News

Oct 14, 2024
pulisher
Oct 14, 2024

Financial Health Report: Ascendis Pharma A/S ADR (ASND)’s Ratios Tell a Tale - The Dwinnex

Oct 14, 2024
pulisher
Oct 09, 2024

Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle

Oct 09, 2024
pulisher
Oct 09, 2024

Stock Market Recap: Ascendis Pharma A/S ADR (ASND) Concludes at 132.05, a -5.10 Surge/Decline - The Dwinnex

Oct 09, 2024
pulisher
Oct 01, 2024

Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily

Oct 01, 2024
pulisher
Sep 30, 2024

Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News

Sep 30, 2024
pulisher
Sep 30, 2024

Ascendis reports positive 3-year hypoparathyroidism trial data - Investing.com

Sep 30, 2024
pulisher
Sep 25, 2024

Results from Ascendis Pharma A/S ADR (ASND) show risk - US Post News

Sep 25, 2024

Ascendis Pharma A S Adr (ASND) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
자본화:     |  볼륨(24시간):